CoChat

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

BACKGROUND Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications. We aimed to assess the efficacy and safety of retatrutide as a monotherapy in people with type 2 diabetes that is inadequately controlled by diet and exercise alone. METHODS In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India, we recruited adults (aged ≥18 years) with type 2 diabetes that is inadequately controlled by diet and exercise alone, glycated haemoglobin (HbA1c) between 7·0% and 9·5% (53-80 mmol/mol), and BMI of at least 23 kg/m2. Participants were randomly assigned (1:1:1:1) to receive retatrutide (4 mg, 9 mg, or 12 mg) or placebo by once-weekly subcutaneous injection. The primary endpoint was the change in HbA1c concentration from baseline to week 40. A key secondary endpoint was the percentage change in bodyweight from baseline to week 40. This trial is registered with ClinicalTrials.gov, NCT06354660, and is completed. FINDINGS Between April 10, 2024, and April 21, 2025, 930 participants were screened and 537 (296 [55%] female and 241 [45%] male) were randomly assigned: 134 to retatrutide 4 mg, 133 to retatrutide 9 mg, 136 to retatrutide 12 mg, and 134 to placebo. Baseline mean age was 48·8 years (SD 12·1), mean HbA1c concentration was 7·9% (SD 1·1), mean duration of diabetes was 2·5 years (SD 4·4), and mean BMI was 35·8 kg/m2 (SD…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(26)00967-0

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 26 references

Research works printed but not linked: 3

  1. 2025, 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026, Diabetes Care, 49, S132
  2. 2025, 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes—2026, Diabetes Care, 49, S166
  3. 2025, 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026, Diabetes Care, 49, S183

Cited by

See all 23

Metadata

Authors
Bajaj, H. S., Welch, M., Shah, P., Luna, E., Jaouimaa, F.-Z., Liu, B., Liu, R., Chen, Y., Patel, H., & Bartee, A.
Affiliations
  • LMC Diabetes & Endocrinology (Canada) (CA)
  • Eli Lilly (United States) (US)
Corresponding author
Bajaj, Harpreet S
Venue
The Lancet
Publisher
Elsevier BV
Published
2026-06
Volume
407
Issue
10546
Pages
2402-2413
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W7163753784
Cited by
23
References
26
Citations by year
2026: 23
FWCI
113.93
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
retatrutide, type 2 diabetes, inadequate glycaemic control, HbA1c, body weight, weight loss, drug safety, adverse events, monotherapy, obesity, subcutaneous injection, HbA1c reduction, body mass index
MeSH terms
Glycemic Control, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Acids, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Peptides, Exercise, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(26)00967-0
The paper
Bajaj, H. S., Welch, M., Shah, P., Luna, E., Jaouimaa, F.-Z., Liu, B., Liu, R., Chen, Y., Patel, H., & Bartee, A. (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(26)00967-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.